The Veet hair removal system for hairy gorillas is flying off the shelf.

This surely has to be a buy? DYOR

http://www.reckittbenckiser.com/

Although Reckitt Benckiser lost its shine last week after cautioning of slower growth in the final quarter, the maker of Mr Sheen and Cillit Bang was yesterday wanted for its defensive attractions. With renewed takeover whispers also swilling round, Reckitt rose 57p to 32.55.

Next Wednesday, it's the turn of household products manufacturer Reckitt Benckiser to provide 2011 figures, so it will be interesting to see how that goes.

Forecasts are currently looking reasonably strong, with a full-year dividend of around 3.7% expected. Like Unilever, Reckitt Benckiser -- whose brands include Dettol, Finish, Scholl, Durex, Nurofen and Cillit Bang -- sells its wares in many countries around the globe, which should help compensate for tough conditions in the US, UK and Europe

Reckitt Benckiser to cut profit reports

The household consumer giant Reckitt Benckiser is set to ditch quarterly reporting of profits amid fears that the long-term growth of the company is under threat.

In a move which is likely to lead to downward pressure on the share price, Rakesh Kapoor, the new chief executive, is also expected to announce that the company is shifting its emphasis from America and Europe, where consumers have cut back drastically on their spending, towards emerging markets, especially China where very few of its brands are sold.

Full Year Results.

Solid top at £35 today. Worth keeping an eye on imho.

Splat - I've been short from 3505 for most of the day :-((

patience skinners :-)

12 month high (3688) hit on results.

Reckitt Benckiser was under the weather on Thursday morning after Credit Suisse downgraded its rating on the stock from 'outperform' to 'neutral' and cut its target price to 3,500p from 3,800p. "Reckitt's historical outperformance in the marketplace was driven by its almost unique ability to garner growth from the developed markets, and in particular Europe the broker said in a research note. "This hasn't been the case for two to three years now, and we don't see that changing any time soon. In part it is the market, but market share is also a contributory factor, and competition isn't about to ease off

RB trying £36 again (3 month high just gone)

New high 3858 hit earlier.

3rd Quarter results

Highlights:

* Year to date like-for-like (LFL) net revenue growth (ex RBP) of +4%, driven
by strong Emerging Markets Areas (EM) growth.

* Strong Q3 LFL growth +5% (+5% ex RBP).

* Europe North America (ENA) Q3 LFL growth +2%. This improved performance was
driven by higher brand equity investment (BEI), a good start for the new
Mucinex Fast Max and a stabilising promotional environment in laundry care
and Vanish.

* YTD global growth driven by Dettol/Lysol, Harpic, Finish, Gaviscon, Durex
and Vanish.

* RBP - volume (mg) market share of Film grown to 60% up from 48% at the end
of 2011.

Consumer brand giant Reckitt Benckiser Group is reaching new high ground, after its shares finished Friday on a new 52-week high of 3,783p. That's 23% up on the price's low point of 3,100p set in November 2011, making 2012 a pretty nice year for shareholders.

Firms making consumer staples, like Reckitt Benckiser and Unilever are often considered good "safety" shares during hard times as they tend to be fairly reliable payers of dividends. Reckitt Benckiser kept its dividend growing during the downturn, and Unilever had only one down year in 2009. The share prices of both are doing well this year.

I'm not sure where they get their figures from, but the 52 week high is 3,858p!

Reckitt Benckiser to acquire Schiff Nutrition

StockMarketWire.com

Reckitt Benckiser Group has signed a definitive merger agreement with Schiff Nutrition International, Inc a leading provider of branded vitamins, nutrition supplements and nutrition bars in the US and elsewhere.

The Board of Directors of Schiff has approved the transaction and will recommend that its stockholders tender their shares into Reckitt Benckiser's previously announced cash tender offer of $42.00 per share, valuing Schiff at $1.4 billion.

Reckitt Benckiser's tender offer will expire at 11:59p.m. New York City time, on December 14, 2012, unless extended in accordance with the merger agreement and the applicable rules and regulations of the SEC.

Reckitt Benckiser will finance the transaction with cash and existing credit facilities. The transaction is expected to be immediately accretive to earnings on an adjusted basis.

New high today.

And again today @4080.

And again @4121.


Massachusetts Financial Services Company > 5%

4200 earlier.

New highs today @4356.

12 February 2013

Reckitt Benckiser ANNOUNCES LATAM OTC COLLABORATION

WITH BRISTOL-MYERS SQUIBB

Slough, England - 12 February, 2013 - Reckitt Benckiser Group PLC ("RB") (LSE:
RBL) today announced that it has signed a three year collaboration agreement
with Bristol-Myers Squibb ("BMS") for a number of market-leading
over-the-counter ("OTC") consumer health care brands in Brazil, Mexico and
certain other parts of Latin America (collectively "BMS Assets"), with an
option to purchase at the end of the three year period. The key brands included
under the agreement are:

Brazil Mexico

Naldecon - leading cough & cold brand Tempra - No.1 in adult and pediatric
pain relief

Luftal - No.1 in anti-flatulence Picot - No.1 in antacids

Dermodex - leading nappy rash brand Graneodin-B - No.1 in sore throat


Under this collaboration, RB will licence the brands from BMS, who will
continue to manufacture them for three years.

Rakesh Kapoor, Reckitt Benckiser Chief Executive Officer, said,

"This transaction creates a material consumer health care platform,
infrastructure and distribution network for RB in both Brazil and Mexico. As
such it is an important step in building our consumer health care presence in
Latin American emerging markets.

"These market-leading brands have strong margins and I firmly believe they have
extremely good growth potential. They fit into our existing OTC categories of
pain relief, sore throat, cough and cold, anti-acid, and dermatological and
will benefit from RB's consumer marketing and Innovation capabilities, and our
significant levels of brand equity investment."

Under the terms of the agreement RB will initially pay BMS $482 million to
enter into the arrangement which also includes personnel, supply contracts and
an option to acquire legal title to the related intellectual property at the
end of the collaboration period, based on business performance. The transaction
will be accounted for as a business combination and the Directors are in the
process of revaluing the assets and liabilities acquired to fair value,
including the value of any acquired intangible assets. Under the terms of a
separate supply agreement BMS will be RB's supplier of the products during the
collaboration period.

BMS Assets had unaudited reported net revenue for the year ended 31 December
2012 of $102 million.

We expect the transaction to be EPS* accretive from 2014 under IFRS. Excluding
the amortization we expect it to be immediately EPS* accretive(1).

The collaboration will come into effect following regulatory approvals,
including anti-trust approvals in the relevant jurisdictions. This is expected
to be completed in Q2 2013.

*Adjusted results exclude the impact of exceptional items

(1) Under IFRS a fair value of the collaboration agreement is required to be
calculated and amortized over the collaboration period.

ENDS